Inside Lesotho's Cannabis Export Push to Europe

Photo by Mohamed Khettouch via Pexels.

Drive up through the Maluti mountains toward Lesotho's higher districts and you'll pass terraced plots where cannabis has grown, quietly and informally, for generations. In 2017, the government made that history official, becoming the first African country to license medical cannabis cultivation for export. The pitch to investors was straightforward: cheap land, altitude that mimics the growing conditions premium European buyers wanted, and a labor force already familiar with the crop. Money followed. Licenses got issued. Headlines called Lesotho the future of African cannabis exports.

Five years on from MG Health becoming Africa's first EU-GMP certified exporter of cannabis active pharmaceutical ingredient to Germany, the industry is still small -- smaller than the early license numbers suggested it would be. A handful of farms are actually running product out the door. Most of the licenses issued in that first wave sit dormant.

The government just moved to address that, standing up two new regulatory bodies inside the last ten months in what amounts to the most significant overhaul of Lesotho's cannabis and medicines framework since 2018. That timing isn't incidental -- it's an admission that the original system, built fast to catch a wave of investor interest, never developed the plumbing to match. Europe wants pharmaceutical-grade product with a clean paper trail from seed to shipment. Lesotho's licensing, testing, and export infrastructure has spent years lagging behind that demand, and the gap is exactly what the new rules are trying to close.

Why Lesotho Bet on Cannabis in the First Place

Photo by Gia Tu Tran via Unsplash.

Lesotho's 2017 decision to license medical and export cannabis cultivation put it ahead of nearly every other African country, and ahead of most conversations happening in European capitals about where pharmaceutical-grade cannabis might come from. The country had two things going for it that neighbors lacked. First, geography: much of Lesotho sits above 1,500 meters, with the Maluti range pushing well past 3,000 meters in places, giving growers the kind of cool nights and intense UV exposure that cannabis cultivators elsewhere spend money replicating indoors. Second, culture: cannabis -- known locally as matekwane or by the regional term dagga -- had been grown informally in Lesotho's highlands for decades, meaning there was already agronomic knowledge on the ground rather than a need to import it wholesale.

Government officials framed the move as economic diversification, and the reasoning made sense on paper. Lesotho's economy has long leaned on a shrinking textile and garment export sector, remittances from Basotho miners working in South Africa, and revenue sharing through the Southern African Customs Union -- none of which offered much room for growth. Cannabis looked like a new column on the balance sheet.

The legal architecture for all this is the Drugs of Abuse (Cannabis) Regulations 2018, amended in 2025. It's worth being precise about what the law actually permits: recreational use remains illegal in Lesotho. What's licensed is cultivation for medical and export purposes, under a permitting regime that in theory covers everything from seed to processed extract. In practice, the clearest proof of concept came in March 2021, when MG Health began shipping cannabis API to Germany as Africa's first EU-GMP certified exporter of the product -- a milestone that, at the time, looked like the start of something much bigger than what's materialized since.

A Sector That Never Scaled: The License Gap

Photo by marcinjozwiak via Pixabay.

The numbers tell a story the early press releases didn't. Lesotho has issued roughly 140 cannabis licenses since the program opened, but a June 2026 analysis from GrowerIQ found only 17 of them still active. That's not a rounding error -- it's the difference between a sector and a paper exercise. A study published through PMC found the certification gap even starker: of 33 licensed entities reviewed, just one held GMP certification, the standard that actually lets a grower sell into regulated European pharmaceutical supply chains rather than sit on a permit with nowhere to ship product.

Put those figures next to the number of farms genuinely running, and the picture sharpens further -- only about five operations are currently producing at commercial scale, out of well over a hundred licenses granted over nearly a decade. Several structural problems explain the die-off. There is no accredited domestic testing laboratory in Lesotho, which means every sample destined for quality verification has to be packaged and shipped across the border to South Africa for analysis -- adding time, cost, and a logistics dependency that smaller operators can't easily absorb.

License fees compound the problem. They were set at a level that made sense for well-capitalized, foreign-backed operations aiming at export from day one, but priced out smaller domestic growers who might otherwise have built a base of mid-tier production. The result is an industry concentrated among a small number of well-financed players, with a long tail of dormant licenses held by entities that never cleared the capital, compliance, or logistics bar to actually cultivate.

And even for the operators who do produce, there's no way around South Africa. Lesotho is landlocked, so every export shipment -- flower, extract, or seed -- has to route through South African ports and roads, meaning Lesotho's export competitiveness is partly hostage to a neighboring country's infrastructure and customs processes it doesn't control.

LeMeRA and the Lesotho Narcotics Bureau: A New Rulebook

Photo by LoboStudioHamburg via Pixabay.

The government's response to that license-versus-output gap arrived over the past ten months in the form of two new bodies built to operationalize the Lesotho Medicines and Medical Devices Control Authority Act, 2023. The first is LeMeRA -- the Lesotho Medicines Regulatory Authority -- which officials have explicitly compared to South Africa's SAHPRA, the regulator that handles medicines and health product approvals there. LeMeRA's board is chaired by Robert Taolana, a pharmacist with a background in public health policy, and its mandate covers the technical review side of licensing: quality, manufacturing standards, and the kind of documentation Europe's pharma buyers actually ask for.

The second body is the Lesotho Narcotics Bureau, which takes over vetting and final sign-off. Under the new structure, license and import/export permit applications go to LeMeRA first for technical review, then move to the LNB for security and narcotics-control clearance before anything is approved. It's a two-stage pipeline where none existed cleanly before -- previously, functions that are now split were bundled together or handled ad hoc, which is part of why processing times and consistency became such a bottleneck.

More is coming. Draft regulations covering marketing authorization, along with Lesotho's first consolidated drug schedules, are expected to be gazetted by the second quarter of the 2026/7 fiscal year -- a step that would give the country a single reference framework instead of the patchwork it's operated under. Parliament backed the buildout with money, approving a M5 million budget (roughly $270,000) in March 2026 specifically for constructing LeMeRA's office.

Health Minister Selibe Mochoboroane has been blunt about the stakes, noting that unregistered drugs are currently entering Lesotho without any fees being paid at all -- a gap he says doesn't exist in South Africa, Botswana, or Namibia, where equivalent regulatory bodies already collect on imports. LeMeRA and the LNB are meant to close that gap, though closing it on paper and closing it in enforcement practice are two different timelines.

What Lesotho Actually Ships to Europe

Dried flower dominates Lesotho's cannabis exports at 65%, followed by high-value extracts at 25%, while seeds make up the smallest share at just 10%.

Strip away the license counts and certification gaps and ask what Lesotho actually sends to Europe, and the figure from the LNDC, the country's national investment promotion agency, comes in at roughly $15 to $20 million a year in cannabis exports. That's a real number, but it's worth sitting with against the scale of ambition the 2017 licensing wave implied -- 140 licenses issued, and the entire sector's annual export value lands in the range of a mid-sized agricultural exporter, not the pharmaceutical growth story that was pitched to investors.

The composition of those exports skews heavily toward the least processed, lowest-margin end of the product line. Dried flower accounts for about 65% of export volume, high-value extracts around 25%, and seeds make up the remaining 10%. That mix is telling: extracts are where the real margin sits, since they're the form pharmaceutical buyers actually want for formulation, and Lesotho is shipping proportionally less of that than flower.

Germany remains the anchor market, and it's anchored almost entirely through MG Health's EU-GMP certified pharmaceutical supply chain -- the same relationship that put Lesotho on the map back in 2021. That's both the sector's proof of concept and its vulnerability: one certified exporter, one primary buyer country, and everyone else largely locked out of that pipeline because they can't clear the GMP bar.

This is where the earlier certification numbers matter most. Europe isn't shopping for cannabis generally -- it's shopping for traceable, pharmaceutical-grade product with documentation that survives an audit. Lesotho has exactly one entity out of 33 licensed operators that can currently meet that standard reliably, and no domestic lab to verify quality without a trip across the South African border. Until that changes, the $15-20 million figure is close to a ceiling, not a floor.

The Next Play: Hemp Fiber and a Regional Foothold

Photo by Petr via Unsplash.

Rather than wait for the pharma bottleneck to resolve itself, the LNDC is pushing a parallel bet: positioning Lesotho as a regional hub for hemp fiber processing. It's a different product category with a different buyer base and, crucially, none of the GMP certification requirements that have throttled flower and extract exports. Fiber doesn't need to clear a pharmaceutical audit to be useful -- it needs a processing facility, a supply of raw material, and buyers in textiles, construction, or industrial materials.

The timing isn't casual. South Africa's Hemp and Cannabis Commercialisation Policy is expected to land by April 2026, and once it does, it's likely to reshape how hemp moves and gets processed across the region -- potentially opening or closing routes for cross-border raw material depending on how the policy is written. Lesotho wants processing capacity built and ready before that policy takes effect, so it can position itself as the place regional hemp fiber gets processed rather than scrambling to catch up afterward.

It's a sound diversification instinct given everything the license and GMP data show about the flower and extract side of the business. Fiber processing plays to infrastructure Lesotho can plausibly build in the near term, rather than requiring the kind of pharmaceutical-grade lab accreditation that's taken years to even get onto the regulatory agenda.

But geography doesn't change with the product category. Lesotho is landlocked no matter what it's shipping, and every route out -- for fiber same as for flower -- runs through South African ports and roads. A hemp fiber hub still depends on South African customs efficiency, trucking capacity, and port access, which means the structural chokepoint that has slowed pharmaceutical exports for years doesn't disappear just because the product on the truck is different.

What's happening in Lesotho right now is a genuine attempt to fix a credibility problem, not just a bureaucratic reshuffle for its own sake. An industry that issued 140 licenses and ended up with five operating farms and one GMP-certified exporter has a legitimacy problem with the exact buyers it's trying to reach, and LeMeRA and the Lesotho Narcotics Bureau are the government's answer to that. Splitting technical review from security vetting, building out a consolidated drug schedule, putting actual budget behind LeMeRA's office -- these are the moves of a government that has read its own numbers and doesn't like what they show.

Whether it actually works is a separate question from whether it's well-intentioned. New regulatory bodies can just as easily add a second layer of delay as they can remove one, and Lesotho's underlying constraints haven't gone anywhere: there's still no accredited domestic testing lab, license fees still price out the smaller growers who might otherwise widen the base beyond a handful of well-capitalized operators, and every shipment still has to clear South African infrastructure that Lesotho has no control over.

If LeMeRA and the LNB manage to actually speed up permitting rather than stack a new bureaucratic step onto an already slow process, Lesotho has a real shot at being one of the few African producers that can meet Europe's pharma-grade standard at meaningful scale, with hemp fiber as a genuine second leg once South Africa's regional policy lands. That's a plausible outcome, not a guaranteed one -- and the gap between those two things is exactly what the next couple of fiscal years will settle.